Insutage 30/70 Injection (3ml Each) contains Human Insulin 100 IU, formulated as a biphasic insulin preparation combining 30% soluble insulin and 70% isophane insulin suspension. This formulation is designed to provide both rapid onset and prolonged glycemic control, making it suitable for the management of diabetes mellitus requiring insulin therapy. The soluble insulin component facilitates prompt reduction of postprandial blood glucose levels, while the isophane insulin ensures sustained basal insulin coverage, thereby maintaining overall glycemic stability. Insutage 30/70 is indicated for patients with type 1 diabetes mellitus and insulin-dependent type 2 diabetes mellitus who require exogenous insulin to achieve optimal blood glucose control. Administration is typically via subcutaneous injection, with dosage individualized based on patient-specific factors including blood glucose monitoring and clinical response. Proper injection technique and rotation of injection sites are essential to minimize local adverse effects such as lipodystrophy. Patients should be counseled on recognizing and managing hypoglycemia, a potential risk associated with insulin therapy. Insutage 30/70 should be stored under recommended conditions to preserve potency. This preparation should be used under medical supervision with regular monitoring to adjust dosage and ensure effective diabetes management.